Myasthenia Gravis (MG) is an autoimmune disorder where the immune system mistakenly attacks the body’s tissues, particularly disrupting the communication between nerves and muscles at the neuromuscular junction. The main autoantibodies responsible for MG target the nicotinic acetylcholine receptor (AChR), followed by muscle-specific kinase (MuSK) and lipoprotein receptor-related protein 4 (LRP4). The condition is characterized by fluctuating muscle weakness, which worsens with physical activity. Initial symptoms often involve weakness in the eye muscles, leading to drooping eyelids (ptosis) and double vision (diplopia). In rare cases, early symptoms may include weakness in the throat or limbs.

For a comprehensive look at the current trends in Myasthenia Gravis, visit DelveInsight’s Myasthenia Gravis Market Infographics.

Epidemiological Breakdown of Myasthenia Gravis

From 2020 to 2034, the epidemiological analysis across the seven major markets (7MM) includes key segments such as:

• Total number of diagnosed prevalent MG cases

• Diagnosed prevalence by gender

• Diagnosed prevalence by age group

• Prevalence based on MGFA classification

• Generalized MG cases by antibody type

Epidemiological Insights

In 2023, approximately 129,000 people in the U.S. were diagnosed with Myasthenia Gravis, with the number expected to increase steadily through 2034. In the EU4 countries (France, Germany, Italy, Spain) and the UK, about 125,000 individuals had been diagnosed, with case numbers projected to rise in the forecast period. Germany had the highest prevalence within the EU4 and UK, reporting 39,000 cases, followed by the UK and France, while Spain had the lowest number. Japan’s diagnosed cases stood at around 32,000 in 2023, with significant growth expected. The highest prevalence was seen in individuals aged 65 and older, while the lowest occurred in children and adolescents (ages 0–17).

Market Overview for Myasthenia Gravis

The Myasthenia Gravis market across the 7MM reached approximately USD 5 billion in 2023.

Market drivers include the increasing prevalence of MG and the aging population, which contribute to higher demand for treatments. Rising competition and innovation, driven by more companies entering the MG treatment space, are also expected to drive market growth. However, the market faces challenges such as limited treatment options for specific MG subtypes, which may impede growth. Additionally, the high cost of new therapies, particularly biologics, could limit patient access.

For more detailed insights into the Myasthenia Gravis market, visit DelveInsight’s Myasthenia Gravis Market Report.

Emerging Therapies in Myasthenia Gravis

A number of promising treatments are currently in development for MG, including:

• UPLIZNA

• Nipocalimab

• ENSPRYNG

• Batoclimab

• Gefurulimab

• Pozelimab + Cemdisiran

• KYV-101

These drugs, along with others in the pipeline, offer hope for improving the treatment of MG.

Key Companies in the Myasthenia Gravis Space

Leading pharmaceutical and biotech companies playing a key role in the MG market include:

• Horizon Therapeutics

• Amgen

• Janssen R&D

• Hoffmann-La Roche

• Immunovant Sciences

• Alexion (AstraZeneca Rare Disease)

• Regeneron Pharmaceuticals

• Kyverna Therapeutics

• Cartesian Therapeutics

• Dianthus Therapeutics

• Takeda

• COUR Pharmaceuticals

• And others.

These companies are advancing the treatment landscape for MG with ongoing research and development.

For a more in-depth analysis of Myasthenia Gravis market dynamics and treatments, check out DelveInsight’s Myasthenia Gravis Market Infographics.